| 5.01 -0.13 (-2.53%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.07 | 1-year : | 9.55 |
| Resists | First : | 6.91 | Second : | 8.18 |
| Pivot price | 5.99 |
|||
| Supports | First : | 4.86 | Second : | 4.04 |
| MAs | MA(5) : | 5.31 |
MA(20) : | 6.28 |
| MA(100) : | 7.8 |
MA(250) : | 6.77  |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 7.7 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 17.39 | Low : | 2.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KZIA ] has closed above bottom band by 17.0%. Bollinger Bands are 26.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.29 - 5.34 | 5.34 - 5.37 |
| Low: | 4.88 - 4.95 | 4.95 - 4.99 |
| Close: | 4.94 - 5.04 | 5.04 - 5.1 |
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Fri, 30 Jan 2026
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com
Wed, 28 Jan 2026
KZIA: HC Wainwright & Co. Reiterates Buy Rating, Price Target Ma - GuruFocus
Tue, 27 Jan 2026
Breast cancer trial drug leaves no detectable disease in one patient - Stock Titan
Thu, 08 Jan 2026
Breast cancer drug update expected this month as Kazia heads to JP Morgan - Stock Titan
Tue, 02 Dec 2025
Kazia Therapeutics raises $50 million in private placement - Investing.com
Tue, 02 Dec 2025
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 853 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 87 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -13.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.61 |
| Profit Margin | 0 % |
| Operating Margin | -268.4 % |
| Return on Assets (ttm) | -64.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -27.3 % |
| Gross Profit (p.s.) | 0.16 |
| Sales Per Share | 0.16 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.38 |
| PEG Ratio | 0 |
| Price to Book value | -1.39 |
| Price to Sales | 31.04 |
| Price to Cash Flow | -4.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|